首站-论文投稿智能助手
典型文献
Dose optimization of intrathecal administration of human umbilical cord mesenchymal stem cells for the treatment of subacute incomplete spinal cord injury
文献摘要:
Human umbilical cord mesenchymal stem cells (hUC-MSCs) are a promising candidate for spinal cord injury (SCI) repair owing to their advantages of low immunogenicity and easy accessibility over other MSC sources. However, modest clinical efficacy hampered the progression of these cells to clinical translation. This discrepancy may be due to many variables, such as cell source, timing of implantation, route of administration, and relevant efficacious cell dose, which are critical factors that affect the efficacy of treatment of patients with SCI. Previously, we have evaluated the safety and efficacy of 4 × 106 hUC-MSCs/kg in the treatment of subacute SCI by intrathecal implantation in rat models. To search for a more accurate dose range for clinical translation, we compared the effects of three different doses of hUC-MSCs – low (0.25 × 106 cells/kg), medium (1 × 106 cells/kg) and high (4 × 106 cells/kg) – on subacute SCI repair through an elaborate combination of behavioral analyses, anatomical analyses, magnetic resonance imaging-diffusion tensor imaging (MRI-DTI), biotinylated dextran amine (BDA) tracing, electrophysiology, and quantification of mRNA levels of ion channels and neurotransmitter receptors. Our study demonstrated that the medium dose, but not the low dose, is as efficient as the high dose in producing the desired therapeutic outcomes. Furthermore, partial restoration of the γ-aminobutyric acid type A (GABAA) receptor expression by the effective doses indicates that GABAA receptors are possible candidates for therapeutic targeting of dormant relay pathways in injured spinal cord. Overall, this study revealed that intrathecal implantation of 1 × 106 hUC-MSCs/kg is an alternative approach for treating subacute SCI.
文献关键词:
作者姓名:
Ting-Ting Cao;Huan Chen;Mao Pang;Si-Si Xu;Hui-Quan Wen;Bin Liu;Li-Min Rong;Mang-Mang Li
作者机构:
Department of Cell Biology,School of Basic Medical Sciences,Southern Medical University,Guangzhou,Guangdong Province,China;Department of Spine Surgery,The Third Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong Province,China;Guangdong Provincial Center for Engineering and Technology Research of Minimally Invasive Spine Surgery,Guangzhou,Guangdong Province,China;Guangdong Provincial Center for Quality Control of Minimally Invasive Spine Surgery,Guangzhou,Guangdong Province,China;Department of Radiology,The Third Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong Province,China
引用格式:
[1]Ting-Ting Cao;Huan Chen;Mao Pang;Si-Si Xu;Hui-Quan Wen;Bin Liu;Li-Min Rong;Mang-Mang Li-.Dose optimization of intrathecal administration of human umbilical cord mesenchymal stem cells for the treatment of subacute incomplete spinal cord injury)[J].中国神经再生研究(英文版),2022(08):1785-1794
A类:
intrathecal
B类:
Dose,optimization,administration,human,umbilical,cord,mesenchymal,stem,cells,treatment,subacute,incomplete,spinal,injury,Human,hUC,MSCs,promising,SCI,repair,owing,their,advantages,low,immunogenicity,easy,accessibility,over,other,sources,However,modest,clinical,efficacy,hampered,progression,these,translation,This,discrepancy,may,due,many,variables,such,timing,implantation,route,relevant,efficacious,which,critical,factors,that,affect,patients,Previously,have,evaluated,safety,by,models,To,search,accurate,range,compared,effects,three,different,doses,medium,high,through,elaborate,combination,behavioral,analyses,anatomical,magnetic,resonance,imaging,diffusion,tensor,DTI,biotinylated,dextran,amine,BDA,tracing,electrophysiology,quantification,levels,channels,neurotransmitter,receptors,Our,study,demonstrated,not,efficient,producing,desired,therapeutic,outcomes,Furthermore,partial,restoration,aminobutyric,acid,type,GABAA,expression,effective,indicates,possible,candidates,targeting,dormant,relay,pathways,injured,Overall,this,revealed,alternative,approach,treating
AB值:
0.551489
相似文献
Urinary bladder cancer as a late sequela of traumatic spinal cord injury
Ralf Böthig;Christian Tiburtius;Wolfgang Schöps;Michael Zellner;Oliver Balzer;Birgitt Kowald;Sven Hirschfeld;Roland Thietje;Aki Pietsch;Ines Kurze;Martin Forchert;Thura Kadhum;Klaus Golka-Department of Neuro-Urology,Centre for Spinal Cord Injuries,BG Klinikum Hamburg,21033 Hamburg,Germany;Urological Practice,53757 Sankt Augustin,Germany;Department of Urology and Neuro-Urology,Johannesbad Fachklinik,94072 Bad Füssing,Germany;Biomechanical Laboratory,Centre for Spinal Cord Injuries,BG Klinikum Hamburg,21033 Hamburg,Germany;Centre for Spinal Cord Injuries,BG Klinikum Hamburg,21033 Hamburg,Germany;Department of Sports and Rehabilitation Medicine,BG Klinikum Hamburg,21033 Hamburg,Germany;Department of Paraplegiology and Neuro-Urology,Centre for Spinal Cord Injuries,Zentralklinik Bad Berka,99437 Bad Berka,Germany;Staff Position Accident Insurance Law,Statutory Accident Insurance for Wood and Metal(BGHM),33602 Bielefeld,Germany;Department of Psychosomatic Rehabilitation,Mittelrheinklinik Fachklinik,56154 Boppard-Bad Salzig,Germany;Clinical Occupational Medicine,Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund(IfADo),44139 Dortmund,Germany
Pharmacodynamic,pharmacokinetic,and phase 1a study of bisthianostat,a novel histone deacetylase inhibitor,for the treatment of relapsed or refractory multiple myeloma
Yu-bo Zhou;Yang-ming Zhang;Hong-hui Huang;Li-jing Shen;Xiao-feng Han;Xiao-bei Hu;Song-da Yu;An-hui Gao;Li Sheng;Ming-bo Su;Xiao-li Wei;Yue Zhang;Yi-fan Zhang;Zhi-wei Gao;Xiao-yan Chen;Fa-jun Nan;Jia Li;Jian Hou-National Center for New Drug Screening,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Yantai Key Laboratory of Nanomedicine&Advanced Preparations,Yantai Institute of Materia Medica,Yantai 264000,China;Department of Hematology,Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200127,China;Shanghai Center for Drug Metabolism and Pharmacokinetics Research,Shanghai 201203,China
Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis
Ying Dong;Bi-xi Tang;Qi Wang;Li-wei Zhou;Cong Li;Xuan Zhang;Dan-dan Sun;Xin Sun;Xue-mei Zhang;Bing Xiong;Jia Li;Hong Shi;Dan-qi Chen;Yi Zang-State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Department of Pharmacology,School of Pharmacy,Fudan University,Shanghai 201203,China;Department of Medicinal Chemistry,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Center for Supramolecular Chemistry and Catalysis and Department of Chemistry,College of Sciences,Shanghai University,Shanghai 200444,China;Schoolof Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing 210023,China;Schoolof Pharmacy,Henan University,Kaifeng 475004,China;Open Studio for Druggability Research of Marine Natural Products,Pilot National Laboratory for Marine Science and Technology(Qingdao),Qingdao 266237,China;School of Pharmaceutical Science and Technology,Hangzhou Institute for Advanced Study,UCAS,Hangzhou 310024,China;Department of Anesthesiology of Shanghai Pulmonary Hospital,School of medicine,Tongji University,Shanghai 200433,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。